Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.
Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.
Prog Lipid Res. 2024 Jul;95:101291. doi: 10.1016/j.plipres.2024.101291. Epub 2024 Aug 8.
Bile acids are steroids formed at the interface of host metabolism and intestinal microbiota. While primary bile acids are generated in the liver from cholesterol metabolism, secondary bile acids represent the products of microbial enzymes. Close to 100 different enzymatic modifications of bile acids structures occur in the human intestine and clinically guided metagenomic and metabolomic analyses have led to the identification of an extraordinary number of novel metabolites. These chemical mediators make an essential contribution to the composition and function of the postbiota, participating to the bidirectional communications of the intestinal microbiota with the host and contributing to the architecture of intestinal-liver and -brain and -endocrine axes. Bile acids exert their function by binding to a group of cell membrane and nuclear receptors collectively known as bile acid-regulated receptors (BARRs), expressed in monocytes, tissue-resident macrophages, CD4+ T effector cells, including Th17, T regulatory cells, dendritic cells and type 3 of intestinal lymphoid cells and NKT cells, highlighting their role in immune regulation. In this review we report on how bile acids and their metabolitesmodulate the immune system in inflammations and cancers and could be exploiting for developing novel therapeutic approaches in these disorders.
胆汁酸是在宿主代谢和肠道微生物群相互作用的界面形成的甾体。虽然初级胆汁酸是在肝脏中由胆固醇代谢生成的,但次级胆汁酸代表微生物酶的产物。在人类肠道中,胆汁酸结构发生了近 100 种不同的酶修饰,而临床指导的宏基因组学和代谢组学分析已经鉴定出数量惊人的新型代谢物。这些化学介质对后生体的组成和功能做出了重要贡献,参与了肠道微生物群与宿主之间的双向交流,并有助于肠道-肝脏-内分泌轴和肠道-大脑-内分泌轴的结构。胆汁酸通过与一组被称为胆汁酸调节受体(BARRs)的细胞膜和核受体结合来发挥作用,这些受体在单核细胞、组织驻留巨噬细胞、CD4+T 效应细胞(包括 Th17、T 调节细胞、树突状细胞和 3 型肠道淋巴细胞和 NKT 细胞)中表达,突出了它们在免疫调节中的作用。在这篇综述中,我们报告了胆汁酸及其代谢物如何在炎症和癌症中调节免疫系统,并可用于开发这些疾病的新型治疗方法。
Prog Lipid Res. 2024-7
Dig Dis Sci. 2021-3
Cells. 2021-5-21
Ann Hepatol. 2017-11
Trends Mol Med. 2015-10-16
Front Immunol. 2018-8-13
Handb Exp Pharmacol. 2019
Autoimmun Rev. 2017-7-8
Cell Mol Immunol. 2025-8-29
Liver Res. 2025-1-28